-
公开(公告)号:US10080785B2
公开(公告)日:2018-09-25
申请号:US11927602
申请日:2007-10-29
IPC分类号: A61K38/00 , A61K38/48 , A61K9/00 , A61K38/21 , A61K38/38 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/65 , C07K14/705 , C07K14/715 , C07K14/76 , C07K14/765 , C12N15/62 , C12N9/96 , A61K47/65 , A61K47/42 , A61K48/00 , A61K39/00
CPC分类号: A61K38/4846 , A01K2217/05 , A61K9/0019 , A61K38/21 , A61K38/212 , A61K38/38 , A61K47/42 , A61K47/65 , A61K48/00 , A61K2039/54 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/65 , C07K14/705 , C07K14/7151 , C07K14/76 , C07K14/765 , C07K2319/00 , C07K2319/21 , C07K2319/31 , C07K2319/50 , C07K2319/75 , C12N9/96 , C12N15/62 , Y02A50/386 , Y02A50/401 , Y02A50/412
摘要: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
-
公开(公告)号:US20130266553A1
公开(公告)日:2013-10-10
申请号:US13464248
申请日:2012-05-04
IPC分类号: C12N9/96
CPC分类号: A61K38/4846 , A01K2217/05 , A61K9/0019 , A61K38/21 , A61K38/212 , A61K38/38 , A61K47/42 , A61K47/65 , A61K48/00 , A61K2039/54 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/65 , C07K14/705 , C07K14/7151 , C07K14/76 , C07K14/765 , C07K2319/00 , C07K2319/21 , C07K2319/31 , C07K2319/50 , C07K2319/75 , C12N9/96 , C12N15/62 , Y02A50/386 , Y02A50/401 , Y02A50/412
摘要: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
-
公开(公告)号:US20100189686A1
公开(公告)日:2010-07-29
申请号:US12365878
申请日:2009-02-04
CPC分类号: A61K38/4846 , A01K2217/05 , A61K9/0019 , A61K38/21 , A61K38/212 , A61K38/38 , A61K47/42 , A61K47/65 , A61K48/00 , A61K2039/54 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/65 , C07K14/705 , C07K14/7151 , C07K14/76 , C07K14/765 , C07K2319/00 , C07K2319/21 , C07K2319/31 , C07K2319/50 , C07K2319/75 , C12N9/96 , C12N15/62 , Y02A50/386 , Y02A50/401 , Y02A50/412
摘要: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
-
公开(公告)号:US20090239795A1
公开(公告)日:2009-09-24
申请号:US11782030
申请日:2007-07-24
CPC分类号: C07K14/57563 , C07K2319/03
摘要: The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.
摘要翻译: 本发明提供融合蛋白,其包含通过多肽接头与转铁蛋白(Tf)融合的毒蜥外泌肽-4以及相应的核酸分子,载体,宿主细胞和药物组合物。 本发明还提供了毒蜥外泌肽-4 / Tf融合蛋白用于治疗II型糖尿病,肥胖症和减轻体重的用途。
-
公开(公告)号:US07507414B2
公开(公告)日:2009-03-24
申请号:US11078663
申请日:2005-03-14
IPC分类号: A61K39/00
CPC分类号: A61K38/4846 , A01K2217/05 , A61K9/0019 , A61K38/21 , A61K38/212 , A61K38/38 , A61K47/42 , A61K47/65 , A61K48/00 , A61K2039/54 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/65 , C07K14/705 , C07K14/7151 , C07K14/76 , C07K14/765 , C07K2319/00 , C07K2319/21 , C07K2319/31 , C07K2319/50 , C07K2319/75 , C12N9/96 , C12N15/62 , Y02A50/386 , Y02A50/401 , Y02A50/412
摘要: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
-
公开(公告)号:US20080269128A1
公开(公告)日:2008-10-30
申请号:US11927617
申请日:2007-10-29
IPC分类号: A61K38/16 , C07K14/775 , C07H21/00 , A61P43/00
CPC分类号: A61K38/4846 , A01K2217/05 , A61K9/0019 , A61K38/21 , A61K38/212 , A61K38/38 , A61K47/42 , A61K47/65 , A61K48/00 , A61K2039/54 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/65 , C07K14/705 , C07K14/7151 , C07K14/76 , C07K14/765 , C07K2319/00 , C07K2319/21 , C07K2319/31 , C07K2319/50 , C07K2319/75 , C12N9/96 , C12N15/62 , Y02A50/386 , Y02A50/401 , Y02A50/412
摘要: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encodings the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the intention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
-
公开(公告)号:US20080261877A1
公开(公告)日:2008-10-23
申请号:US11927593
申请日:2007-10-29
CPC分类号: A61K38/4846 , A01K2217/05 , A61K9/0019 , A61K38/21 , A61K38/212 , A61K38/38 , A61K47/42 , A61K47/65 , A61K48/00 , A61K2039/54 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/65 , C07K14/705 , C07K14/7151 , C07K14/76 , C07K14/765 , C07K2319/00 , C07K2319/21 , C07K2319/31 , C07K2319/50 , C07K2319/75 , C12N9/96 , C12N15/62 , Y02A50/386 , Y02A50/401 , Y02A50/412
摘要: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encodings the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the intention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
-
公开(公告)号:US5847086A
公开(公告)日:1998-12-08
申请号:US487445
申请日:1995-06-07
IPC分类号: C12N15/09 , A61K38/00 , A61K38/36 , A61P7/02 , A61P9/00 , A61P43/00 , C07K1/22 , C07K14/745 , C07K14/755 , A61K35/14
CPC分类号: C07K14/755 , A61K38/00
摘要: Processes for preparing aqueous solutions of cysteine-altered von Willebrand Factor fragment which are substantially free of aggregate and capable of therapeutic use for treating thrombosis are provided. The claimed process comprises providing an aqueous solution of vWF fragment and denaturant and containing undesired contaminants, said solution having an acidic pH; separating said contaminants from said solution by contacting said solution with an affinity chromatography medium to which said vWF fragments adhere; eluting said vWF fragment from said affinity chromatography medium in the presence of the denaturant; and separating the eluted fragment from said denaturant while maintaining the aqueous solution of the fragment at a pH of about 2.5 to less than about 5.5 to increase monomerization of, and decrease aggregation of, said fragment, thereby forming an aqueous solution of vWF fragment which is substantially free of aggregate.
摘要翻译: 提供了制备基本上不含聚集体并能治疗用于治疗血栓形成的半胱氨酸改变的血管性血友病因子片段的水溶液的方法。 所要求的方法包括提供vWF片段和变性剂的水溶液并含有不期望的污染物,所述溶液具有酸性pH; 通过使所述溶液与所述vWF碎片粘附到的亲和层析介质接触来分离所述污染物; 在变性剂存在下,从所述亲和层析介质中洗脱所述vWF片段; 并将洗脱的片段与所述变性剂分离,同时将片段的水溶液保持在约2.5至小于约5.5的pH,以增加所述片段的单体化和降低聚集,由此形成vWF片段的水溶液,其为 基本上不含聚集体。
-
公开(公告)号:US20120252732A1
公开(公告)日:2012-10-04
申请号:US13212879
申请日:2011-08-18
CPC分类号: A61K38/4846 , A01K2217/05 , A61K9/0019 , A61K38/21 , A61K38/212 , A61K38/38 , A61K47/42 , A61K47/65 , A61K48/00 , A61K2039/54 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/65 , C07K14/705 , C07K14/7151 , C07K14/76 , C07K14/765 , C07K2319/00 , C07K2319/21 , C07K2319/31 , C07K2319/50 , C07K2319/75 , C12N9/96 , C12N15/62 , Y02A50/386 , Y02A50/401 , Y02A50/412
摘要: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
-
公开(公告)号:US20110245178A1
公开(公告)日:2011-10-06
申请号:US12956623
申请日:2010-11-30
CPC分类号: C07K14/57563 , C07K2319/03
摘要: The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.
摘要翻译: 本发明提供融合蛋白,其包含通过多肽接头与转铁蛋白(Tf)融合的毒蜥外泌肽-4以及相应的核酸分子,载体,宿主细胞和药物组合物。 本发明还提供了毒蜥外泌肽-4 / Tf融合蛋白用于治疗II型糖尿病,肥胖症和减轻体重的用途。
-
-
-
-
-
-
-
-
-